Covance Appoints VP of Clinical Development Services - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Covance Appoints VP of Clinical Development Services



Covance reported that Barry J. Goldstein, MD, PhD, has joined its clinical development services business as vice-president and global therapeutic area head of the expanded cardiovascular, metabolic, endocrine, and renal unit.  In this new role, Goldstein will join the medical & scientific affairs leadership team and will be based in Princeton, NJ.
 
Goldstein joins Covance from Merck where he served as vice-president in clinical research and therapeutic area head for diabetes and endocrinology, since 2008.  In this role, he managed Merck’s Phase II-IV clinical development team for a large portfolio including diabetes, obesity, osteoporosis, and women’s health.  His responsibilities included strategic input to proof-of-concept study designs, clinical trial strategies, protocol development, regulatory filings, responses to payer inquiries, lifecycle management activities, as well as pharmacovigilance and post-marketing studies. In addition to his biopharmaceutical industry experience, Goldstein’s medical career includes serving as director, division of endocrinology, diabetes & metabolic diseases, Jefferson Medical College at Thomas Jefferson University in Philadelphia from 1992 to 2008.  His most recent academic roles include professor of medicine, biochemistry and molecular pharmacology at Jefferson from 1997 to 2008.
 
Source: Covance

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here